insights_auto
Why is ONCY down 8,63%?
Dive Deeperchevron_right
ONCY:NASDAQ
Oncolytics Biotech Inc
0,54 US$
arrow_downward
-8,63%(-0,051) 1D
0,54 US$
arrow_downward
-0,77% (-0,0042)todayPre-market
Closed: 8 ოქტ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONCY...
Open
0,60 US$
High
0,61 US$
Low
0,54 US$
Mkt. cap
70,88 მლნ.
Avg. vol.
1,02 მლნ.
Volume
165,00
52-wk high
1,32 US$
52-wk low
0,54 US$
Beta
1,15
Shares outstanding
127,51 მლნ.
No. of employees
29
Open
0,60 US$
High
0,61 US$
Low
0,54 US$
Mkt. cap
70,88 მლნ.
Avg. vol.
1,02 მლნ.
Volume
165,00
52-wk high
1,32 US$
52-wk low
0,54 US$
Beta
1,15
Shares outstanding
127,51 მლნ.
No. of employees
29
News stories
From web sources and news partners
Endpoints News
·
56 წუთის წინ
TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension
Yahoo Finance
·
2 საათის წინ
Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial
Simply Wall Street
·
24 წუთის წინ
Does Mirum Pharmaceuticals (MIRM) Trade At A Discount On Sales?
Seeking Alpha
·
1 საათის წინ
S&P 500 Sector Outlook: Favor XLC And XLK, Underweight XLP With Uneven Earnings Leadership
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc